As of September 30, 2019 and December 31, 2018, the Company's accrued expenses balance consists of the following (in thousands): | | | | | | | | | | | | | September 30, 2019 | | December 31, 2018 | Accrued clinical trial expenses | $ | 4,988 | | | $ | 6,635 | | Accrued professional fees | 9,421 | | | 13,398 | | Accrued technical operation expenses | 10,176 | | | 9,371 | | Accrued royalty payable | 1,830 | | | 409 | | Accrued interest payable | 1,663 | | | 3,631 | | Accrued sales allowances and related costs | 4,640 | | | 818 | | Accrued construction costs | 4,693 | | | 2,946 | | Other accrued expenses | 1,497 | | | 1,046 | | | $ | 38,908 | | | $ | 38,254 | |
|